Month: June 2021

68 shareholders were registered as attending at the Annual General Meeting, who owned 497,278,196 votes/shares (the amount of represented share capital 233,720,725 EUR), forming 74.23% of AS Tallink Grupp share capital. Resolutions adopted at the meeting: 1. To approve the Annual Report of 2020 of AS Tallink Grupp presented by the Management Board. In favour of the resolution voted 100% of the votes represented at the meeting (497,277,169 votes).   2. To approve the proposal presented by the management board of AS Tallink Grupp:1) To approve the net loss of the financial year of 2020 in the amount of 108,308,000 euros and to cover the net loss with the retained earnings;2) No dividend distribution to the shareholders. In favour of the resolution voted 100% of the votes represented at the meeting (497,271,167 votes).   3. To amend the second...

Aleafia Health’s Port Perry Outdoor Cultivation Site86 acre outdoor cultivation facilityTORONTO, June 15, 2021 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”), a global leader in cannabis wellness products and services, today announced that it has largely completed planting across 86 acres at its outdoor cultivation facility in Port Perry, Ont. The milestone was achieved a month earlier, and on a significantly larger scale, than the 2020 outdoor season, which yielded 31,200 kgs of dried flower, at a cash cost to harvest of $0.10 per gram. “Through the tremendous diligence and hard work of our operations team, we are poised to take another major step forward this year in outdoor cultivation. With all infrastructure completed and licences secured last year,...

– CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events – – Initiating Cohort 2 patient screening for 0.1 mg dose in June 2021 – ALPHARETTA, Ga., June 15, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector® in six patients (n=6) with neovascular age-related macular degeneration (wet AMD). The primary endpoints were achieved in Cohort 1, as the initial...

HONKARAKENNE OYJ Stock Exchange Release 15 June 2021 at 14:00 EET CHANGE IN HONKARAKENNE OYJ’S HOLDING OF TREASURY SHARES Honkarakenne Oyj has assigned 10 000 Honkarakenne B-shares as a part of CEO’s performance-based incentive for year 2020. The handover date for the shares was 8 June 2021. After the transfer, Honkarakenne group holds 339 385 of its own class B shares. HONKARAKENNE OYJ Board of Directors Further information: Marko Saarelainen, President and CEO, tel. +358 40 542 0254, marko.saarelainen@honka.com orMaarit Jylhä, Vice President, Finance – CFO, tel. +358 40 594 4099, maarit.jylha@honka.com DISTRIBUTION Nasdaq Helsinki LtdKey mediaFinancial Supervisory Authoritywww.honka.com Honkarakenne supplies high-quality, healthy and ecological log homes, holiday homes and public buildings. Its buildings are made from Finnish solid...

DODGEVILLE, Wis., June 15, 2021 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) today announced that the Company will be participating in the Jefferies Virtual Consumer Conference on Tuesday, June 22, 2021 with a fireside chat presentation at 8:35 AM Eastern Time. The audio portion of the fireside chat presentation will be webcast live over the internet and can be accessed on the investor relations section of its website at http://investors.landsend.com. An online archive will be available for a period of 90 days following the presentation. About Lands’ End, Inc. Lands’ End, Inc. (NASDAQ:LE) is a leading uni-channel retailer of casual clothing, accessories, footwear and home products. Operating out of America’s heartland, we believe our vision and values make a strong connection with our core customers. We offer products...

TORONTO, June 15, 2021 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM) (“Wallbridge” or the “Company”) today announced the appointment of Ms. Danielle Giovenazzo, Ph.D, P.Geo, as a Director of the Company. Based in Montreal, Quebec, Ms. Giovenazzo has over 35 years’ experience in exploration, principally for gold, Ni-Cu-PGEs, base metals and rare earth elements. In addition to her expertise in mineral exploration in Canada and internationally with a range of companies including Newmont-Goldcorp, Falconbridge and Xstrata Nickel, Ms. Giovenazzo brings significant management, project management, project generation and board experience to Wallbridge. Most recently, Ms. Giovenazzo was an independent director of SOQUEM, a subsidiary of Ressources Québec and leader in Quebec’s mineral exploration industry. “Danielle’s expertise...

Reno, Nevada, June 15, 2021 (GLOBE NEWSWIRE) — Brookmount Explorations, Inc. (OTC Pink: BMXI) (“Brookmount”) is pleased to announce that it has entered into a binding agreement with Gennex Gold Corp. pursuant to which Gennex Gold will sell to Brookmount its entire interest in the Moosehorn Gold Project in Yukon, Canada, situated approximately 20km south of the Trans Alaska Highway, near Dawson City. The project covers approximately 6,000 hectares, and includes an accommodation camp, airstrip, fuel depot and a comprehensive inventory of heavy equipment including excavators, diggers, ore trucks and a large ball mill. The acquisition also includes all relevant and exploration and production related licenses and permits. Existing gold reserves have been partially surveyed under 43-101 requirements, resulting in an initial estimated...

At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo Rapid onset of treatment effect was seen in HAMD-17 results at Days 3, 8, and 12 Patients with a response at Day 15 to zuranolone retained on average 86% of their HAMD-17 improvement at Day 42 (4 weeks after dosing ended) Zuranolone was generally well-tolerated and demonstrated a safety profile consistent with previous clinical studies; trial completion rate was 90.3% in the zuranolone group Zuranolone is an investigational two-week, once-daily oral drug for MDD that represents a potential new class of drug for the management of this common but serious mental health disorderCAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) — Sage Therapeutics,...